Clinical Trial Update: Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial of the indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas has completed, with results posted in December 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• LMP744 (indenoisoquinoline topoisomerase I inhibitor)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Solid Tumors, Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2024-12-10